GlassScriptPhysician profile
Thomas G Harrington
NPI 1447348115
$3,531.60
in general payments reported to CMS, 2019-2025
38 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $217 · 2021: $18.33 · 2022: $441 · 2023: $905 · 2024: $514 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.26 |
| Education | $150.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $630.92 | 2019-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $465.86 | 2023-2025 | Orgovyx, Gemtesa |
| Procept Biorobotics Corporation | $253.12 | 2019-2024 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $200.32 | 2019-2025 | Xtandi |
| Pfizer INC. | $166.24 | 2023-2025 | |
| Urogen Pharma, INC. | $153.55 | 2023-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $130.48 | 2019-2025 | |
| Myovant Sciences INC. | $122.22 | 2022 | |
| Endo Pharmaceuticals INC. | $119.68 | 2019-2024 | Xiaflex, Aveed, Edex |
| Endo USA, INC. | $118.29 | 2024-2025 | Xiaflex, Aveed |
| Dendreon Pharmaceuticals LLC | $106.49 | 2022-2025 | Provenge |
| Olympus America INC. | $95.34 | 2025 | Itind System |
| Teleflex LLC | $87.68 | 2022-2024 | Urolift |
| C. R. Bard, INC. & Subsidiaries | $86.99 | 2019 | |
| Abbvie INC. | $79.26 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $64.98 | 2019-2025 | Adstiladrin |
| Ge Healthcare | $61.73 | 2023 | |
| Rochester Medical Corporation | $59.53 | 2019-2020 | |
| Boston Scientific Corporation | $55.56 | 2024 | Greenlight Xps |
| Merck Sharp & Dohme LLC | $54.10 | 2022-2024 | Bridion |
| Tolmar, INC. | $36.03 | 2023-2024 | |
| Neotract INC. | $35.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Progenics Pharmaceuticals, INC. | $29.32 | 2025 | |
| Immunitybio, INC. | $28.14 | 2025 | |
| 180 Medical, INC. | $26.78 | 2019 | |
| Accord Healthcare, INC. | $24.98 | 2025 | |
| Urovant Sciences INC | $22.91 | 2022 | |
| Coloplast Corp | $22.06 | 2023 | Speedicath |
| Emd Serono, INC. | $21.84 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.78 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.76 | 2025 | |
| Photocure INC | $20.69 | 2025 | Cysview |
| Tolmar Pharmaceuticals, INC. | $18.28 | 2022 | |
| Mimedx Group, INC. | $16.04 | 2024 | |
| Antares Pharma, INC. | $15.98 | 2019 | |
| Blue Earth Diagnostics | $12.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Harrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.